胺DNA糖酶的向诱导在p53缺乏的癌症中产生合成致死性
Jia-Xin Zhou1, Zhen-Yu Shao1, Lin Zhang2
1State Key Laboratory of Epigenetic Regulation and Intervention, Shanghai Key Laboratory of Molecular Andrology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
使用C-271向甲胺DNA糖酶 (TDG) 会导致p53缺乏癌症的合成致死性. 这种新的方法通过破坏DHX9和激活免疫路径来抑制瘤,提供了一种新的治疗策略.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 药物发现 药物发现 药物发现
背景情况:
- 乙胺DNA糖酶 (TDG) 在DNA修复,脱甲基和转录中起着关键作用,影响发育和癌症.
- 在癌症进展中TDG的精确机制及其治疗向仍然未得到充分研究.
研究的目的:
- 调查针对TDG在癌症中的治疗潜力.
- 阐明TDG在p53缺乏癌症中的作用背后的分子机制.
主要方法:
- 开发C-271,一种针对TDG的新型小分子抑制剂.
- 在临床前癌症模型中评估C-271的疗效.
- 涉及基因表达分析和通路激活试验 (RIG-I/MDA5-MAVS) 的机制研究.
主要成果:
- 用C-271准TDG在抑制p53-缺乏瘤方面表现出显著的治疗疗效.
- 在p53缺乏的细胞中,TDG抑制导致DHX9下调和异常积累双链RNA (dsRNA).
- 累积的dsRNA激活了RIG-I/MDA5-MAVS通路,导致瘤抑制和增强抗瘤免疫力.
结论:
- TDG和p53表现出合成致命性,使得TDG在p53缺乏癌症中成为可行的治疗点.
- C-271代表了对p53缺乏癌症的有前途的第一类抑制剂,利用了一种新的作用机制.
- TDG抑制提供了一种潜在的策略,通过dSRNA介导途径激活来增强抗瘤免疫力.
更多相关视频
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
12:19Uracil-DNA Glycosylase Assay by Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry Analysis
Published on: April 22, 2022
相关概念视频
DNA Base Pairing
Targeted Cancer Therapies
There are several types of targeted therapies against...
Lethal Alleles
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
DNA as a Genetic Template
The DNA Helix
Complementary DNA
